SIGA Technologies, Inc.  

(Public, NASDAQ:SIGA)   Watch this stock  
Find more results for Rose Haynes�
2.73
+0.09 (3.41%)
Real-time:   1:58PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.64 - 2.73
52 week 2.49 - 4.15
Open 2.64
Vol / Avg. 57,621.00/300,960.00
Mkt cap 145.62M
P/E     -
Div/yield     -
EPS -0.30
Shares 53.34M
Beta 1.98
Inst. own 32%
Jun 2, 2014
SIGA Technologies at Jefferies Global Healthcare Conference
May 15, 2014
SIGA Technologies Annual Shareholder Meeting
May 1, 2014
Q1 2014 SIGA Technologies Earnings Conference Call - Webcast
May 1, 2014
Q1 2014 SIGA Technologies Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -615.53% -311.22%
Operating margin -1026.25% -426.07%
EBITD margin - -408.39%
Return on average assets -6.64% -11.46%
Return on average equity -87.76% -75.97%
Employees 34 -
CDP Score - -

Address

Suite 1700, 660 Madison Avenue
NEW YORK, NY 10065
United States - Map
+1-212-6729100 (Phone)
+1-212-6973130 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

SIGA Technologies, Inc. (SIGA) is a pharmaceutical company specializing in the development and commercialization of pharmaceutical solutions for some of the lethal disease-causing pathogens in the world - smallpox, Ebola, dengue, Lassa fever and other dangerous viruses. Its business is to discover, develop, manufacture and successfully commercialize drugs to prevent and treat these high-priority threats. The Company's focuses to disarm dreaded viral diseases and create robust, modern biodefense countermeasures. The Company�s product include ST-246, is an orally administered antiviral drug that targets orthopoxviruses. The Company�s lead product, ST-246, is an orally administered antiviral drug that targets orthopoxviruses. On May 13, 2011, it signed the BARDA Contract pursuant to which it agreed to deliver two million courses of ST-246 to the Strategic Stockpile.

Officers and directors

Eric A. Rose M.D. Chairman of the Board, Chief Executive Officer
Bio & Compensation  - Reuters
Daniel J. Luckshire Chief Financial Officer, Executive Vice President, Secretary
Age: 42
Bio & Compensation  - Reuters
William J. Haynes Executive Vice President, General Counsel
Age: 55
Bio & Compensation  - Reuters
Dennis E. Hruby Ph.D. Chief Scientific Officer, Vice President
Age: 61
Bio & Compensation  - Reuters
James J. Antal CPA Independent Director
Age: 62
Bio & Compensation  - Reuters
Michael J. Bayer Independent Director
Age: 65
Bio & Compensation  - Reuters
William C. Bevins Independent Director
Bio & Compensation  - Reuters
Thomas E. Constance Independent Director
Age: 76
Bio & Compensation  - Reuters
Jeffrey B. Kindler Independent Director
Age: 58
Bio & Compensation  - Reuters